Boston Scientific EVP adds shares via 401(k)

Accepted by SEC EDGAR 08/03/2026 - 04:29 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Boston Scientific Corp executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported a discretionary acquisition of 64,198 shares of common stock on 2026-07-31 through a rebalance of his holdings under the company’s 401(k) Retirement Savings Plan at $46.73 per share. These shares are held indirectly via the 401(k), which now reflects that balance. Separate entries show 213,907 shares held directly and 5,234 shares held by his child, with a footnote stating he disclaims beneficial ownership of the child’s shares.

Insider Trade Summary

Discretionary: 64,198 shares

Discretionary 1 txn

Insider Fitzgerald Joseph Michael

Role EVP & Group Pres, Cardiology

Type	Security	Shares	Price	Value
Discretionary	Common Stock F1, F2	64,198	$46.73	$3.00M
Holding	Common Stock	--	--	--
Holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 64,198 shares (Indirect, By 401(k)); Common Stock — 213,907 shares (Direct); Common Stock — 5,234 shares (Indirect, By Child)

Holdings Before and After: Common Stock, 0 to 64,198 shares (Indirect, By 401(k))

Footnotes (3)

1. F1. Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
2. F2. Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
3. F3. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.

Key Figures

Shares acquired via 401(k) rebalance: 64,198 shares Acquisition price per share: $46.73 per share Indirect 401(k) holdings after transaction: 64,198 shares +2 more

5 metrics

Shares acquired via 401(k) rebalance 64,198 shares Discretionary transaction under Rule 16b-3(f) on 2026-07-31

Acquisition price per share $46.73 per share Price for common stock in 401(k) discretionary transaction

Indirect 401(k) holdings after transaction 64,198 shares Balance in Boston Scientific 401(k) Retirement Savings Plan

Direct holdings after transaction 213,907 shares Common stock held directly by Joseph Fitzgerald

Child’s reported holdings 5,234 shares Indirect holdings "By Child" with beneficial ownership disclaimed

Key Terms

Rule 16b-3(f), 401(k) Retirement Savings Plan, discretionary transaction, beneficial ownership

4 terms

Rule 16b-3(f) regulatory

"Discretionary transaction under Rule 16b-3(f)"

401(k) Retirement Savings Plan financial

"under the Company's 401(k) Retirement Savings Plan"

discretionary transaction financial

"which resulted in a discretionary transaction in shares"

beneficial ownership financial

"The reporting person disclaims beneficial ownership of the shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Boston Scientific (BSX) executive Joseph Fitzgerald report?

Joseph Fitzgerald reported a discretionary acquisition of 64,198 Boston Scientific common shares on 2026-07-31 through a rebalance of his holdings in the company’s 401(k) Retirement Savings Plan, recorded at a price of $46.73 per share.

How many Boston Scientific (BSX) shares are in Joseph Fitzgerald’s 401(k) after the reported transaction?

Following the transaction, Fitzgerald’s company 401(k) account holds 64,198 Boston Scientific shares. A footnote states this balance reflects the most current data available for his holdings under the company’s 401(k) Retirement Savings Plan.

Was Joseph Fitzgerald’s Boston Scientific (BSX) share acquisition a discretionary plan transaction?

Yes. The filing describes the event as a discretionary transaction under Rule 16b-3(f), resulting from an election by Fitzgerald to rebalance his holdings within Boston Scientific’s 401(k) Retirement Savings Plan, rather than a standard open-market trade.

How many Boston Scientific (BSX) shares does Joseph Fitzgerald hold directly after this filing?

The Form 4 indicates that Fitzgerald holds 213,907 Boston Scientific common shares in direct ownership as of 2026-07-31. This direct holding is separate from shares reported as held indirectly through the company 401(k) plan or by his child.

Does Joseph Fitzgerald claim beneficial ownership of Boston Scientific (BSX) shares held by his child?

No. While 5,234 shares are reported as held indirectly “By Child”, a footnote explicitly states that Fitzgerald disclaims beneficial ownership of these shares and that the report should not be deemed an admission of beneficial ownership.

What rule governs the reported discretionary Boston Scientific (BSX) transaction in Fitzgerald’s 401(k)?

The transaction is characterized as a discretionary transaction under Rule 16b-3(f). This designation reflects that the acquisition of Boston Scientific shares arose from a discretionary rebalance election within the company’s 401(k) Retirement Savings Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Joseph Michael

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Group Pres, Cardiology

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		I(1)		64,198	A	$46.73	64,198(2)	I	By 401(k)
Common Stock								213,907	D
Common Stock								5,234(3)	I	By Child

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

2. Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

3. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.

	/s/ Susan Thompson, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)